Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-5222 vs Co-administered Components in Healthy Adults
NCT06993181Phase 1Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-5222 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
DA-5222
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06993181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993181.